AVBP - NASDAQ
ArriVent BioPharma, Inc. Common Stock
$29.78
-0.47%ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
At a Glance
Live Snapshotavbp
Selling, General and Administrative Expenses
Last Annual Value
24.18M
3-Year CAGR
55%
5-Year CAGR
61%
10-Year CAGR
27%
ArriVent BioPharma, Inc. Common Stock Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 24.18M | 35.6% | 60.6% | N/A | |
 Erasca, Inc. NASDAQ:ERAS | 38.55M | 0.7% | 11.3% | N/A | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 18.90M | 40.7% | N/A | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 0.00 | N/A | N/A | N/A | |
 Arvinas, Inc. NASDAQ:ARVN | 89.40M | -3.8% | 7.7% | 39.5% | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 183.29M | -21.9% | -26.6% | N/A | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 152.32M | 12.5% | 12.7% | 24.4% | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 52.90M | 3.8% | 3.9% | 24.3% | |
 Astria Therapeutics, Inc. NASDAQ:ATXS | 35.25M | 11.1% | 18.9% | 13.3% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 120.59M | 17.1% | 33.0% | N/A |
ArriVent BioPharma, Inc. Common Stock Fair Value Envelope
Related Guides
Continue your AVBP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.